New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown....

Full description

Bibliographic Details
Main Authors:	Brendan L. Mangan, Dilan Patel, Heidi Chen, Katie S. Gatwood, Michael T. Byrne, Salyka Sengsayadeth, Stacey Goodman, Bhagirathbhai Dholaria, Adetola A. Kassim, Madan Jagasia, Wichai Chinratanalab, Kathryn A. Culos, Brian G. Engelhardt
Format:	Article
Language:	English
Published:	Wiley 2020-11-01
Series:	eJHaem
Subjects:	haploidentical hematopoietic cell transplant posttransplant diabetes mellitus
Online Access:	https://doi.org/10.1002/jha2.70

Similar Items

Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
by: Emmanuel Katsanis, et al.
Published: (2020-07-01)

Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
by: Madoka Kanda-Kato, et al.
Published: (2020-09-01)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
by: Rafael Hernani, et al.
Published: (2021-05-01)

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
by: Samuel Cytryn, et al.
Published: (2020-04-01)

Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
by: Jacopo Mariotti, et al.
Published: (2020-01-01)

A case of posttransplant lymphoproliferative disorder
by: G S Chowdhary, et al.
Published: (2017-01-01)

The prognostic value of posttransplant chimerism
by: A. A. Sipol, et al.
Published: (2022-11-01)

Current status of conditioning regimens in haploidentical hematopoietic cell transplantation
by: Junichi Sugita, et al.
Published: (2024-12-01)

Early posttransplant granulomatous interstitial nephritis
by: Sriram Sriperumbuduri, et al.
Published: (2017-01-01)

Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I
by: Motoi Yamashita, et al.
Published: (2022-10-01)

Posttransplant vesical calculi – A case series
by: Dimple Kumar Chanamolu, et al.
Published: (2019-01-01)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
by: Masaya Abe, et al.
Published: (2021-01-01)

Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia
by: Xin-Yu Li, et al.
Published: (2022-11-01)

Posttransplant lymphoproliferative disorder coexisting with extrapulmonary tuberculosis: A diagnostic dilemma
by: Mohammed Shoeb Ahmed Khan, et al.
Published: (2018-01-01)

Histopathological Features of Time-Zero Kidney Biopsy Are Predictive Factors for Posttransplant Anemia
by: Mislav Mokos, et al.
Published: (2023-06-01)

Incidence and relative risk factors in posttransplant diabetes mellitus patients: a retrospective cohort study
by: Ching-Yao Cheng, et al.
Published: (2020-12-01)

Posttransplant Lymphoproliferative Disorder Involving the Gastrointestinal Tract
by: Tejas Kirtane, et al.
Published: (2020-12-01)

Haploidentical stem cell transplant: Established treatment, expanding horizons
by: Mukul Aggarwal, et al.
Published: (2016-01-01)

Haploidentical hematopoietic cell transplant recipient presents with late‐onset Epstein Barr virus‐associated posttransplant lymphoproliferative disorder
by: Adam Braun, et al.
Published: (2023-08-01)

Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney RecipientsPlain-Language Summary
by: David A. Axelrod, et al.
Published: (2022-01-01)

Isolated B cell central nervous system posttransplant lymphoproliferative disorder: Role of magnetic resonance imaging in the diagnosis and management in the absence of neurological signs - a case report
by: Monisha Jacob, et al.
Published: (2020-01-01)

Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient
by: Juan Hu, et al.
Published: (2023-09-01)

Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
by: Razan Mohty, et al.
Published: (2024-12-01)

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
by: Ting-Ting Yang, et al.
Published: (2021-04-01)

Burkitt’s Lymphoma Presenting as Late-Onset Posttransplant Lymphoproliferative Disorder following Kidney and Pancreas Transplantation: Case Report and Review of the Literature
by: Seema Naik, et al.
Published: (2013-01-01)

Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls
by: Jacopo Mariotti, et al.
Published: (2020-11-01)

Late-onset posttransplant lymphoproliferative disease in a male kidney transplant patient on minimal triple immunosuppressive therapy: Diagnosis and management
by: Sneha Haridas Anupama, et al.
Published: (2019-01-01)

Influence of ABO compatibility on haploidentical hematopoietic stem-cell transplant
by: Rajesh B Sawant, et al.
Published: (2023-01-01)

Waiting-List and early posttransplant prognosis among ethnoracial groups: Data from the organ procurement and transplantation network
by: Yangyang Wu, et al.
Published: (2023-01-01)

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
by: Rebecca E. Schultze-Florey, et al.
Published: (2018-06-01)

Incidence of new-onset diabetes and posttransplant metabolic syndrome after liver transplantation - A prospective Study From South India
by: Tittu Oommen, et al.
Published: (2020-01-01)

Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model
by: Leland Metheny, et al.
Published: (2018-02-01)

Strategies in Haploidentical Stem Cell Transplantation in Adults
by: Ulaş D. Bayraktar, et al.
Published: (2013-12-01)

Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
by: Bjoern-Thore Hansen, et al.
Published: (2021-12-01)

A pediatric case series of catastrophic gastrointestinal complications of posttransplant lymphoproliferative disease with increasing incidence, high association with coronavirus disease 2019, higher mortality, and a plea for early endoscopy to prevent late fatal outcome
by: Alireza Keshtkar, et al.
Published: (2023-09-01)

Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide
by: Giuseppe Lia, et al.
Published: (2022-01-01)

Posttransplant Immune Activation
by: Didier Ducloux, et al.
Published: (2017-09-01)

Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study
by: Sarah S. Alghanem, et al.
Published: (2020-11-01)

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
by: Yu Wang, et al.
Published: (2019-09-01)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
by: Salyka Sengsayadeth, et al.
Published: (2022-01-01)